← Back to Clinical Trials
Recruiting NCT05620329

NCT05620329 UNC Pleural Fluid Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05620329
Status Recruiting
Phase
Sponsor UNC Lineberger Comprehensive Cancer Center
Condition Lung Cancer
Study Type OBSERVATIONAL
Enrollment 9,999 participants
Start Date 2018-01-24
Primary Completion 2050-01-24

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 9,999 participants in total. It began in 2018-01-24 with a primary completion date of 2050-01-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid registry for use in future studies.

Eligibility Criteria

Inclusion Criteria: * Patients who are 18 years or older * Inpatients and outpatients * Diagnosed with pleural fluid, are referred for and undergo clinically indicated drainage who have clinical evidence of: * pulmonary infection (such as fever, leukocytosis, new or worsening infiltrate on chest x-ray, or clinical deterioration) with effusion * malignancy Exclusion Criteria: * A subject will not be eligible for inclusion in this registry if, in the investigator's (or treating clinician's) opinion, the patient has any concurrent medical condition that may preclude their ability to undergo pleural fluid drainage safely. * Incarcerated individuals

Contact & Investigator

Central Contact

Carmmen Garcia

✉ carmmene@med.unc.edu

📞 +1 954-336-7499

Principal Investigator

Jason Akulian

PRINCIPAL INVESTIGATOR

UNC Lineberger Comprehensive Cancer Center

Frequently Asked Questions

Who can join the NCT05620329 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05620329 currently recruiting?

Yes, NCT05620329 is actively recruiting participants. Contact the research team at carmmene@med.unc.edu for enrollment information.

Where is the NCT05620329 trial being conducted?

This trial is being conducted at Chapel Hill, United States.

Who is sponsoring the NCT05620329 clinical trial?

NCT05620329 is sponsored by UNC Lineberger Comprehensive Cancer Center. The principal investigator is Jason Akulian at UNC Lineberger Comprehensive Cancer Center. The trial plans to enroll 9,999 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology